Tag: SARA31
Biophytis: FDA approval for the Sara-31 study in the United States
(AOF) – Biophytis has received authorization from the FDA (Food and Drug Administration) to launch its Sara-31 study in the United States, the first phase 3 study ever launched in…
Biophytis obtains FDA authorization to start the SARA-31 phase 3 study in sarcopenia – 09/11/2023 at 07:00
Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative processes linked to…
Biophytis obtains a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe
(AOF) – Biophytis SA (a clinical-stage biotechnology company specializing in the development of treatments that aim to slow the degenerative processes associated with aging) announces today that it has received…
Biophytis has applied to the FDA for authorization to launch the SARA-31 phase 3 study in sarcopenia
By Claude Leguilloux Published on 07/10/2023 at 07:32 (Boursier.com) — Biophytis SA, a clinical-stage biotechnology company specializing…
Biophytis has applied to the FDA for authorization to launch the SARA-31 phase 3 study in sarcopenia – 07/10/2023 at 07:00
Paris (France) and Cambridge (Massachusetts, United States), July 10, 2023 – 7:00 a.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company…
Biophytis has applied to the EMA for authorization to launch the SARA-31 phase 3 study in sarcopenia – 05/15/2023 at 08:00
Paris, France, Cambridge (Massachusetts, United States), May 15, 2023 – 8:00 a.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company at…